Design and Characterization of Ceritinib Eutectic Solvent Systems for Pharmaceutical Formulation

One of the main challenges facing the pharmaceutical industry today is the low solubility of active pharmaceutical ingredients (APIs), which leads to low bioavailability, reduced therapeutic efficacy, and the need for higher drug doses. Eutectic solvents (ES) offer a promising solution by effectively dissolving APIs, creating API-ES systems that can significantly improve drug solubility and delivery. In this study, three distinct ESs were prepared by combining various components, with their successful formation confirmed through Fourier Transform Infrared Spectroscopy. Key physicochemical properties, including the density, viscosity, and pH of the prepared solvents, were subsequently determined. Ceritinib (CRT), an API utilized in the treatment of non-small cell lung cancer, was then incorporated into the prepared ESs to yield the API-ES systems. A comparative analysis was conducted to assess the release profiles of pure CRT versus CRT within the API-ES systems. Furthermore, the permeability and diffusion coefficient of the drug within these systems were also determined. The results conclusively demonstrated that the formation of the API-ES system increased the solubility of CRT in water. This achievement represents a vital initial step toward optimizing the delivery of this drug and highlights the significant potential for developing a novel, improved pharmaceutical formulation.